Optimizing Antiviral Dosing for HSV and CMV Treatment in Immunocompromised Patients

• Egile Nagusiak: Daan W. Huntjens (Egilea), Jacob A. Dijkstra (Egilea), Lisanne N. Verwiel (Egilea), Mirjam Slijkhuis (Egilea), Paul Elbers (Egilea), Matthijs R. A. Welkers (Egilea), Agnes I. Veldkamp (Egilea), Marianne A. Kuijvenhoven (Egilea), David C. de Leeuw (Egilea), Heshu Abdullah-Koolmees (Egilea), Maria T. Kuipers (Egilea), Imke H. Bartelink (Egilea)
• Formatua: Liburua
• Argitaratua: MDPI AG, 2023-01-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Herpes simplex virus (HSV) and cytomegalovirus (CMV) are DNA viruses that are common among humans. Severely immunocompromised patients are at increased risk of developing HSV or CMV disease due to a weakened immune system. Antiviral therapy can be challenging because these drugs have a narrow therap...